ERBB2 and breast carcinoma: Inhibition of stromal SDF-1–dependent CXCR4 activation by CXCR4 inhibitors attenuates myofibroblast content, tumor angiogenesis, and tumor growth in patient-derived tumor xenografts from Her2+ human breast cancers (Lefort et al, 2017).